Zhou Zizhen, Yan Xiaoluan, Shi Wanwan, Tan Kangan, Shao Chen, Wang Yan, Wang Guiqiang, Hong Yuan
Infectious Diseases Department, Peking University First Hospital, Beijing, China.
General Surgery Department, Beijing Cancer Hospital, Beijing, China.
J Gastrointest Oncol. 2022 Apr;13(2):732-743. doi: 10.21037/jgo-21-715.
Tumor-derived organoid, namely tumoroid, can realistically retain the clinicopathologic features of original tumors even after long-term expansion. Here we develop this production methodology derived from hepatocellular carcinoma primary samples and generate a platform to evaluate the tumoricidal efficacy of autologous adoptive cell transfer including tumor infiltrating lymphocytes and peripheral blood lymphocytes.
Haematoxylin and eosin together with immunohistochemistry staining were employed to ascertain the morphologic and histological features of tumoroids and original tumors. Tumor killing ability of T cells was detected by lactate dehydrogenase assay and propidium iodide staining. In tumoroid xenograft mouse model, tumor volumes were measured and T cell functions were examined by flow cytometry technique.
Four tumoroids with characteristics of poor differentiation and mild fibrosis were successfully established from fourteen hepatocellular carcinoma samples. More robust antitumor potential and hyper-functional phenotype of all four tumor infiltrating lymphocytes were observed compared to matched peripheral blood lymphocytes in coculture system. In tumoroid xenograft mouse models, however, only one patient-derived tumor infiltrating lymphocytes with the highest antitumor activity can bestow efficient tumor eradication.
Hepatocellular carcinoma tumoroid-based models could represent invaluable resources for evaluating the tumoricidal efficacy of autologous adoptive cell transfer. Tumor infiltrating lymphocytes should be a promising and yet-to-be-developed regimen to treat hepatocellular carcinoma.
肿瘤来源的类器官,即肿瘤样组织,即使在长期扩增后也能真实保留原发肿瘤的临床病理特征。在此,我们开发了这种源自肝细胞癌原发样本的生产方法,并构建了一个平台来评估包括肿瘤浸润淋巴细胞和外周血淋巴细胞在内的自体过继性细胞转移的杀瘤效果。
采用苏木精-伊红染色和免疫组织化学染色来确定肿瘤样组织和原发肿瘤的形态学和组织学特征。通过乳酸脱氢酶测定和碘化丙啶染色检测T细胞的肿瘤杀伤能力。在肿瘤样组织异种移植小鼠模型中,测量肿瘤体积,并通过流式细胞术技术检测T细胞功能。
从14例肝细胞癌样本中成功建立了4个具有低分化和轻度纤维化特征的肿瘤样组织。在共培养系统中,与匹配的外周血淋巴细胞相比,观察到所有4种肿瘤浸润淋巴细胞具有更强的抗肿瘤潜力和超功能表型。然而,在肿瘤样组织异种移植小鼠模型中,只有1例具有最高抗肿瘤活性的患者来源的肿瘤浸润淋巴细胞能够有效根除肿瘤。
基于肝细胞癌肿瘤样组织的模型可能是评估自体过继性细胞转移杀瘤效果的宝贵资源。肿瘤浸润淋巴细胞应该是一种有前景但尚未开发的治疗肝细胞癌的方案。